Connect with us

Health

Pregnant women hospitalised for COVID-19 infection do not face increased death risk: Study

Published

on



ANI |
Updated:
May 12, 2021 13:26 IST

Washington [US], May 12 (ANI): Pregnant women who develop severe COVID-19 infections that require hospitalisation for pneumonia and other complications may not be more likely to die from these infections than non-pregnant women.
In fact, they may have significantly lower death rates than their non-pregnant counterparts. The study, conducted by researchers at the University of Maryland School of Medicine (UMSOM), was published in the journal ‘Annals of Internal Medicine’.
The study examined medical records from nearly 1,100 pregnant women and more than 9,800 non-pregnant patients aged 15 to 45 who were hospitalised with COVID-19 and pneumonia. Slightly less than 1 per cent of the pregnant patients died from COVID-19 compared to 3.5 per cent of non-pregnant patients, according to the study findings.
There are, however, some important caveats to the study data in terms of differences between the two populations. Pregnant patients were more likely to be younger and have fewer health conditions, including diabetes, obesity, hypertension, and chronic lung disease, compared to the non-pregnant patients.
Given the small number of deaths seen in the study, the researchers were unable to control for these differences to determine whether they significantly affected mortality risk.

“I think this is reassuring news for women who are pregnant and worried about getting infected with COVID-19 as new variants emerge,” said study corresponding author Anthony Harris, MD, MPH, Professor of Epidemiology and Public Health at UMSOM.
“While the study does not tell us for certain that pregnancy does not pose added risks for women, the data certainly point in that direction,” added Harris.
Researchers from The University of Texas Health Science Center at Houston also participated in this study. UMSOM faculty who were co-authors of this study include Katherine Goodman, JD, PhD, Lisa Pineles, MA, Lyndsay O’Hara, PhD, Gita Nadimpalli, MD, MPH, Laurence Magder, PhD, and Jonathan Baghdadi, MD, PhD.
“I am so pleased we can provide some reassuring news to pregnant women who have faced an added burden during the COVID-19 pandemic,” said E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine.
“This is an important study that adds to our knowledge of the COVID-19 pandemic at a critical time,” concluded Reece. (ANI)

Advertisement

Health

Adenoiditis: Causes, who is at risk, signs and symptoms, diagnosis, treatment | Health

Published

on

By

Adenoiditis is a type of health condition wherein the adenoids (tissue behind the nose and above the throat) gets inflamed and it is common among children and leads to problems like snoring, mouth breathing, recurrent ear infections, decreased hearing, difficulty in breathing, cracked lips, runny nose and bad breath. Adenoiditis occurs when there is inflammation of the adenoid tissue resulting from infection, allergies or irritation from stomach acid as a component of laryngopharyngeal reflux (LPR).

Adenoiditis: Causes, who is at risk, signs and symptoms, diagnosis, side effects, treatment (Photo by Twitter/DrMary_Alphonse)
Adenoiditis: Causes, who is at risk, signs and symptoms, diagnosis, side effects, treatment (Photo by Twitter/DrMary_Alphonse)

In an interview with HT Lifestyle, Dr Nitty Mathew, Senior Specialist – ENT at Aster CMI Hospital, revealed, “Adenoiditis is usually caused by an infection of adenoids. Adenoids become apparent by 2 years of age and regress in size after 8 years. If these remain swollen for a prolonged time, then they can become problematic.”

Highlighting who is at risk of developing adenoiditis, she shared that since adenoids usually shrink by adulthood, children are most susceptible to its infection. They can be more prone to developing adenoiditis if the child is

● Bottle fed

● Breast fed in lying down position

Advertisement

● Have an infection near the nose or throat

● Suffering from an allergy

According to her, the symptoms of adenoiditis include:

● Stuffy and blocked nose

● Snoring

Advertisement

● Sleep apnea

● Cracked lips, dry mouth

● Glue ear

● Ear pain and infections

● Swollen neck glands

Advertisement

She said, “To diagnose adenoiditis, your doctor will conduct a check-up of your child’s nose, ears, mouth and throat. In case the symptoms are worse, your doctor may also suggest he/she undergo an X-ray to see degree of enlargement of adenoids and obstruction of nasal airway.”

Talking about the side effects of adenoiditis, Dr Nitty Mathew pointed out that the complications of untreated adenoiditis include –

● Runny nose

● Recurrent ear infections, decreased hearing

● Dry mouth, Dental caries

Advertisement

● Speaking with a nasal tone

● Adenoid facies

The health expert added, “Adenoid facies is defined as the open -mouthed appearance in children, associated with a narrow nose, shortened upper lip, narrow palate, high palatal vault and dental crowding.” She concluded, “Usually by 8years of age adenoids regress, but keeping good hygiene can prevent repeated infections. Mild symptoms warrants only supportive treatment, but if your doctor suspects any bacterial infection then the child will have to be treated with antibiotics and then kept on nasal sprays to decrease the size of adenoids. In case the medications are not bringing intended relief of symptoms, then a surgery called adenoidectomy to remove the enlarged adenoids will have to be done.”

Advertisement
Continue Reading

Health

Researchers explain: What causes long Covid breathing problems

Published

on

By

Researchers at Stanford University have found that people are experiencing breathing problems post Covid-19 due to a condition known as lung fibrosis in which the damaged lungs form scar tissue, that makes it difficult for the lungs to expand and contract.

The research showed that overactivity of genes that regulate inflammation and immune responses leads to lung fibrosis.

Long Covid cases can be severely debilitating and resistant to treatment, said Gerlinde Wernig, Assistant Professor of pathology, at Stanford University.

What`s worse, lung function can continue to decline, even without a new Covid-19 infection, Wernig said.

Advertisement

The finding published in the Proceedings of the National Academy of Sciences offers hope that, one day, targeted drugs could intervene to quell the genes behind the damage.

In the study, the team started by looking at lung tissue samples from five Covid-19 patients who had symptoms of the disease — such as shortness of breath — for one or more months. The lungs of people who had symptoms after infection with SARS-CoV-2 looked like the lungs of people with end-stage pulmonary fibrosis.

By analysing single cells from the patients` tissue samples, the scientists also saw similarities in the pattern of RNA production — which can hint a cell`s overall function — between samples of tissue from long Covid patients and samples from patients with pulmonary fibrosis.

“We saw this same pattern across all human Covid lung samples,” Wernig said.

As with other lung infections, the initial Covid-19 infection in the lungs kicked off an inflammatory process. In the case of long-Covid patients, however, the immune dysfunction keeps going long after the virus is gone — similar to what happens in chronic pulmonary fibrosis.

Advertisement

To test whether lung fibrosis could be firmly connected to Covid infections, they looked at lung fibrosis in mice infected with a SARS-CoV-2-like virus and found significant increases in fibrosis and immune dysfunction.

“Innate immune cells go crazy after that infection,” Wernig said, referring to the part of the immune system that forms the first line of defence against pathogens.

In a mouse model engineered to more closely represent human biology, researchers showed that, when the mice contracted SARS-CoV-2, scarring in the lung tissues shot up, as did levels of immune cells interleukin-6, CD47 and pJUN. There was also a bright side to these experiments.

“When we did the same experiments but blocked CD47 and Il-6, we saw very little fibrosis,” Wernig said. “This hints at possible treatments for long Covid involving drugs that carry out targeted immune blockades.”

Also Read: Mumbai: All wards have Covid-19 cases; only one critical

Advertisement

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

Continue Reading

Health

89Bio’s NASH drug meets main goals of mid-stage study, Health News, ET HealthWorld

Published

on

By

89Bio's NASH drug meets main goals of mid-stage study

New Delhi: Drug developer 89Bio Inc said on Wednesday its treatment for a liver disease called non-alcoholic steatohepatitis met the main goals of a mid-stage trial, sending its shares up 50 per cent in premarket trading.

The company’s experimental drug, Pegozafermin, demonstrated at least one-stage fibrosis improvement without worsening of NASH and NASH resolution without worsening of fibrosis in both trial doses.

89Bio said the data supports advancement to late-stage development.

Follow and connect with us on , Facebook, Linkedin, Youtube

Advertisement

Continue Reading

Trending